SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

GoldCoin is experiencing fragmented discussion, with traders primarily debating its performance against other precious metals and cryptocurrencies, while also noting ongoing geopolitical tensions and central bank gold repatriation efforts as potential long-term macro factors. Many participants are expressing frustration with the asset's recent price action compared to better-performing mining stocks and other momentum trades.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive topline Phase 3 IZAR-1 trial results, though shares faced downward pressure as the data were perceived as competitive rather than demonstrating clear superiority. Traders are currently debating the company's valuation, the impact of continued share dilution, and the long-term potential of its sonelokimab therapy as the company progresses toward a BLA submission for hidradenitis suppurativa.

Polygon

The community is debating the asset's performance, with many traders expressing frustration over lagging price action and potential insider selling, while others maintain a bullish outlook based on network upgrades, payment integration, and transition to a fully independent Layer 1.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

The Internet Computer (ICP) community continues to focus heavily on the network's technological capabilities, such as AI integration, decentralized cloud infrastructure, and sovereign applications, while debating the impact of ongoing market volatility and historical price performance. Traders are actively monitoring infrastructure developments and ecosystem updates, expressing a mix of long-term conviction in the project's utility and frustration over recent stagnant price action.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased community interest driven by its recent v5.0 mainnet upgrade, which introduces post-quantum cryptographic features, and persistent anticipation regarding potential regulatory developments like the Clarity Act. While some traders are expressing optimism about the project's long-term technical potential and institutional adoption, others remain skeptical, citing historical price underperformance and ongoing concerns about token dilution.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is receiving attention as traders speculate on its potential for a price reversal, citing its low circulating supply and institutional pivot efforts as key factors. The community remains divided, with some expressing frustration over persistent underperformance compared to other altcoins while others view current price levels as an accumulation opportunity.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors monitor the company's progress toward regulatory milestones for its lead CRISPR-based candidate, Lonvo-z, with many noting the significance of its non-dilutive financing and potential for future commercialization. While some traders express optimism regarding the company's gene-editing platform and institutional support, others highlight concerns about cash burn, potential dilution, and the competitive biotech landscape.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as traders discuss potential ecosystem developments, including upcoming game launches, the DO Chain rollout, and ongoing speculation regarding supply burns and a potential repeg of USTC. While sentiment is divided, many in the community emphasize long-term growth prospects, despite some skepticism over market volatility and the impact of the wider crypto landscape.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

MUU is trending as traders capitalize on the high volatility and rebound momentum of the memory sector, with many discussing leveraged strategies and the stock's significant price swings. Community sentiment remains largely focused on technical setups, cyclical recovery, and anticipation of upcoming company earnings.

First Majestic Silver Corp. engages in the production, development, exploration, and acquisition of mineral properties, with a focus on silver and gold production in North America. It owns and operates producing mines in Mexico, including the Santa Elena Silver & Gold Mine, the Los Gatos Silver Mine, the San Dimas Silver & Gold Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA, which is currently in the process of restarting. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as traders react to extreme volatility and conflicting sentiment regarding the sector's long-term outlook, with many pointing to the influence of institutional margin requirements and macroeconomic factors like interest rates and bond yields. While some community members remain optimistic about silver's potential for price discovery, others express frustration over persistent downward pressure and the perceived disconnect between the metal's industrial demand and the performance of mining equities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Canaccord Genuity Group Lowers Compass Therapeutics (NASDAQ:CMPX) Price Target to $7.00

Canaccord Genuity Group dropped their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday...

Citizens Jmp Reiterates Market Outperform Rating for Compass Therapeutics (NASDAQ:CMPX)

Citizens Jmp restated a "market outperform" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Tuesday...

Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month Low  - What's Next?

Compass Therapeutics (NASDAQ:CMPX) Reaches New 52-Week Low - Here's Why...

Compass Therapeutics Touts Stunning PFS Win in COMPANION-002 as Crossover Muddy OS Data

Compass Therapeutics (NASDAQ:CMPX) executives highlighted what CEO and Vice Chair Dr. Thomas Schuetz called absolutely stunning progression-free survival results from the company's phase II/III...

Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients

Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study, but data shows progression-free survival and response rates.read more...

Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated a "buy" rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Monday...

This Small-Cap Biotech Is Gearing Up For A Make-Or-Break Cancer Drug Data Drop

Equity

The biotech firm is set to report topline data on secondary endpoints from its Phase 2/3 trial for advanced biliary tract cancer on Monday.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Bearish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Current Price	$2.38
Prev Close	$2.37
Open	$2.34
Dividend Yield	0.00%
50-Day Moving Average	$2.22
Beta	1.56
Avg. Volume	3.22M
PE Ratio	-5.91

52-Week High	$6.88
52-Week Low	$1.61
Market Capitalization	$428.61M
EPS (Annual)	-$0.4216
Price to Book	2.58
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CMPX Fundamentals